Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products; Revised Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a revised dr...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Federal Register
- Region
- USA
- Scope
- Regulatory
- Published
- June 24, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a revised dr...
Source route
Continue on federalregister.gov
Leave the platform to read the original full article on the publisher site.
Source: Federal Register
Scope: Regulatory
Related coverage
More related coverage
Legionellosis in residents of England and Wales: 2025
This report presents data from the National Enhanced Legionnaires' Disease Surveillance Scheme (NELS...
Martha's Rule extended to all maternity services
Landmark patient safety initiative, Martha's Rule, rolled out to all maternity settings after review...
Clostridioides difficile infection: how to deal with the problem
Interim update to the guidance on the most effective methods of prevention and control of Clostridio...
Ockenden review into maternity services at Nottingham University Hospitals NHS Trust: final report
Findings, conclusions and essential actions from the independent review of maternity services at Not...